Replimune (REPL) Return on Capital Employed (2018 - 2025)
Replimune's (REPL) quarterly Return on Capital Employed came in at 104.65% in Q4 2025, down 5673.0% year-on-year from 1.88% in Q4 2024, and down 23.13% quarter-over-quarter from 84.99% in Q3 2025.
Replimune (REPL) Return on Capital Employed (2018 - 2025) Analysis & Trends
Replimune has disclosed Return on Capital Employed across 8 years of filings, most recently posting 104.65% for Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 104.65%, down 5673.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 104.65% (down 5673.0% YoY), and the FY2025 annual result was 57.23%, down 1266.0% from the prior year.
- Return on Capital Employed came in at 104.65% for Q4 2025 at Replimune, down from 84.99% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.9% in Q1 2021 to a low of 104.65% in Q4 2025.
- The 5-year median for Return on Capital Employed is 36.69% (2022), against an average of 42.08%.
- Across the five-year window, Return on Capital Employed soared 949 bps in 2021 and plunged 5673 bps in 2025, its largest moves.
- Replimune's Return on Capital Employed stood at 22.79% in 2021, then dropped by 29 bps to 29.4% in 2022, then plunged by 53 bps to 44.99% in 2023, then declined by 7 bps to 47.92% in 2024, then slumped by 118 bps to 104.65% in 2025.
- The last three Return on Capital Employed figures came in at 104.65% (Q4 2025), 84.99% (Q3 2025), and 65.36% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | -104.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -104.65% |
| Sep 30, 2025 | -84.99% |
| Jun 30, 2025 | -65.36% |
| Mar 31, 2025 | -50.79% |
| Dec 31, 2024 | -47.92% |
| Sep 30, 2024 | -48.98% |
| Jun 30, 2024 | -49.72% |
| Mar 31, 2024 | -49.96% |
| Dec 31, 2023 | -44.99% |
| Sep 30, 2023 | -39.41% |
| Jun 30, 2023 | -32.35% |
| Mar 31, 2023 | -28.16% |
| Dec 31, 2022 | -29.40% |
| Sep 30, 2022 | -33.98% |
| Jun 30, 2022 | -29.96% |
| Mar 31, 2022 | -26.15% |
| Dec 31, 2021 | -22.79% |
| Sep 30, 2021 | -19.94% |
| Jun 30, 2021 | -17.27% |
| Mar 31, 2021 | -14.90% |